(Press-News.org) A University of Rochester Medical Center study published in the Journal of Clinical Oncology, challenges treatment guidelines for early stage follicular lymphoma, concluding that six different therapies can bring a remission, particularly if the patient is carefully examined and staged at diagnosis.
The research underlines the fact that when cancer strikes, modern patients and their oncologists across the United States are taking many diverse treatment paths when there is scant data to support one method over another. This study suggests that the old standard approach – radiation therapy, alone – is no longer the best choice for early follicular lymphoma, according to researchers at the James P. Wilmot Cancer Center at URMC.
Lead author Jonathan W. Friedberg, M.D., acting director of the Wilmot Cancer Center and chair of Hematology/Oncology at URMC, pointed out that the earlier recommendation for radiation was based on uncontrolled experiences at select institutions.
"As we move into an era focused on quality, we need research like this to help us determine the true effectiveness of various therapies when definitive studies are lacking," Friedberg said. "The choice of treatment should be based on whether it produces remission and survival. And if the outcomes are equivalent, then we'll need to consider toxicities and tolerance of therapies, as well as cost. We hope our data will assist physicians in making decisions with patients."
Researchers followed 471 patients for up to 10 years. The study is believed to be the largest of early-stage follicular lymphoma (FL) in the modern treatment era.
All patients were identified through a disease registry called National LymphoCare, which includes more than 2,700 cases diagnosed between 2004 and 2007, at 200 medical practices in the U.S.
As the definition of stage 1 FL changed over time, so did the way doctors evaluated and diagnosed patients. Two groups emerged in the study: People who received a comprehensive staging exam, which included imaging tests and a bone marrow biopsy, and people who were not carefully staged. The latter group had more recurrences and individuals were less likely to survive. This finding emphasizes the importance of a rigorous evaluation at diagnosis as the best way to predict the prognosis, Friedberg said.
Among all patients, researchers observed six treatment approaches, from a conservative watch-and-wait strategy to an aggressive combination of chemotherapy and radiation.
An important goal of the Wilmot study was to better understand the outcomes associated with the various treatment options, since no data so far has proven that one therapeutic approach is better than another for early-stage FL. Researchers noted that only 34 percent of patients with stage 1 FL were treated with the recommended radiation therapy, according to their analysis of the national cancer database.
Of the 206 patients who were carefully staged, a greater percentage also chose more aggressive therapy, such as an immunotherapy-chemotherapy combination (28 percent versus 17 percent of non-rigorously staged patients) or chemo and radiation (13 percent versus 6 percent non-rigorously staged patients).
Although the overall survival outcomes were the same for both groups, the patients who were most carefully evaluated at diagnosis had superior progression-free survival, which means the cancer did not relapse as often. (FL is characterized by frequent relapses, even if treatment controls the relapses.) During a median follow-up of 57 months, 21 percent of the staged patients experienced FL progression.
An estimated 66,000 people in the U.S. were diagnosed with non-Hodgkin lymphoma in 2011. Follicular lymphoma is the most common form of non-Hodgkin lymphoma. Most often it occurs in older people. FL is usually slow-growing; an early symptom is lymph node enlargement. Although not curable, the median five-year survival rate is about 75 percent and patients can live for many years, even after relapses. Approximately 26 percent of people who have FL are diagnosed at stage 1.
INFORMATION:
Genentech funded the research. The drug company, a member of the Roche Group, makes Rituxan (rituximab), approved by the U.S. Food and Drug Administration in 1997as the first therapeutic antibody in for cancer. It is often indicated for follicular lymphoma. Additional funding came from the National Cancer Institute SPORE grant, which supports a lymphoma research partnership between the URMC and University of Arizona Cancer Center.
END
Chimpanzees from African sanctuaries carry drug-resistant, human-associated strains of the bacteria Staphlyococcus aureus, a pathogen that the infected chimpanzees could spread to endangered wild ape populations if they were reintroduced to their natural habitat, a new study shows.
The study by veterinarians, microbiologists and ecologists was the first to apply the same modern sequencing technology of bacterial genomes used in hospitals to track the transmission of staph from humans to African wildlife. The results were published Aug. 21 by the American Journal of Primatology.
Drug-resistant ...
RIVERSIDE, Calif. (www.ucr.edu) — Research by Nosang Myung, a professor at the University of California, Riverside, Bourns College of Engineering, has enabled a Riverside company to develop an "electronic nose" prototype that can detect small quantities of harmful airborne substances.
Nano Engineered Applications, Inc., an Innovation Economy Corporation company, has completed the prototype which is based on intellectual property exclusively licensed from the University of California. The device has potential applications in agriculture (detecting pesticide levels), industrial ...
Investigators at Nationwide Children's Hospital may have discovered a biological explanation for why low levels of oxygen advance spinal muscular atrophy (SMA) symptoms and why breathing treatments help SMA patients live longer. The findings appear in Human Molecular Genetics.*
SMA is a progressive neurodegenerative disease that causes muscle damage and weakness leading to death. Respiratory support is one of the most common treatment options for severe SMA patients since respiratory deficiencies increase as the disease progresses. Clinicians have found that successful ...
MADISON – Acinetobacter baumanni, a pathogenic bacterium that is a poster child of deadly hospital acquired infections, is one tough customer.
It resists most antibiotics, is seemingly immune to disinfectants, and can survive desiccation with ease. Indeed, the prevalence with which it infects soldiers wounded in Iraq earned it the nickname "Iraqibacter."
In the United States, it is the bane of hospitals, opportunistically infecting patients through open wounds, catheters and breathing tubes. Some estimates suggest it kills tens of thousands of people annually.
But ...
Fueling nuclear reactors with uranium harvested from the ocean could become more feasible because of a material developed by a team led by the Department of Energy's Oak Ridge National Laboratory.
The combination of ORNL's high-capacity reusable adsorbents and a Florida company's high-surface-area polyethylene fibers creates a material that can rapidly, selectively and economically extract valuable and precious dissolved metals from water. The material, HiCap, vastly outperforms today's best adsorbents, which perform surface retention of solid or gas molecules, atoms ...
On Aug. 24, NASA will launch two identical satellites from Cape Canaveral, Fla., to begin its Radiation Belt Storm Probes (RBSP) mission to study the extremes of space weather and help scientists improve space weather forecasts.
Why should you care?
Because, says a University of Iowa space physics researcher, if you've ever used a cell phone, traveled by plane, or stayed up late to catch a glimpse of the northern lights, then you have been affected by space weather without even knowing about it.
Scientists want to better understand how the Van Allen radiation belts—named ...
The menopause evolved, in part, to prevent competition between a mother and her new daughter-in-law, according to research published today (23 August 2012) in the journal Ecology Letters.
The study – by researchers from the University of Turku (Finland), University of Exeter (UK), University of Sheffield (UK) and Stanford University (US) – explains for the first time why the relationship women had with their daughter-in-laws could have played a key role.
The data showed that a grandmother having a baby later in life, and at the same time as her daughter-in-law, resulted ...
An internationally recognized melanoma researcher at Moffitt Cancer Center and colleagues at the University of Kiel in Germany, including Axel Hauschild, M.D. and Katharina C. Kähler, M.D., have published an article in the current issue of The Journal of Clinical Oncology that describes immune-related adverse events for patients receiving either tremelimumab or ipilimumab, the latter a drug approved last year by the U.S. Food and Drug Administration for treating metastatic melanoma and other cancers.
Both drugs are anti-CTLA-antibodies with similar mechanisms of action, ...
Circular Energy has completed the installation of over 426kW of solar energy systems, spanning five apartment complexes in the Dallas-Fort Worth area. All of the complexes are managed by Centaurus Property Management, who commissioned the projects. The properties are located in Dallas, Farmers Branch, Irving and Fort Worth.
JC Shore, CEO of Circular Energy, notes, "This was a tough set of projects for us to execute in such a short time frame. I'm thrilled with our teams' leadership and the hard work of our installation crews. It's neat to be able to deliver the ...
The World Human Resources Development (HRD) Congress presented Pinnacle Performance Company with its 2012 Best Training Provider and Innovation in Learning Awards for Excellence in Learning and Development.
The World HRD awards identify and honor individuals, teams and organizations that have used learning and development to significantly advance workforce productivity and performance.
"We created Pinnacle Performance Company to deliver a unique training experience that could improve anyone's communication skills in a short amount of time and provide tools for ...
